000			05790cam a2200841Ii 4500
001			sulb-eb0032238
003			BD-SySUS
005			20170713221325.0
006			m o d
007			cr cnu|||unuuu
008			130204t20132013gw ac ob 001 0 eng d
040			_aDG1 _beng _erda _epn _cDG1 _dEBLCP _dN$T _dMHW _dYDXCP _dCOO _dIDEBK _dE7B _dNOC _dOCLCF _dIUL _dSCB _dOCLCQ _dCDX _dNKT _dOCLCQ _dBD-SySUS
019			_a828869678 _a828896125 _a961601655 _a962705463
020			_a9783527651085 _q(electronic bk.)
020			_a352765108X _q(electronic bk.)
020			_a9783527651115 _q(electronic bk.)
020			_a352765111X _q(electronic bk.)
020			_a9781299241206 _q(MyiLibrary)
020			_a1299241204 _q(MyiLibrary)
020			_z9783527330737
020			_z3527330739
029	1		_aAU@ _b000050562533
029	1		_aAU@ _b000053030546
029	1		_aDKDLA _b820120-katalog:000655918
029	1		_aNLGGC _b382514440
029	1		_aNZ1 _b15340091
029	1		_aDEBBG _bBV043395341
035			_a(OCoLC)826637765 _z(OCoLC)828869678 _z(OCoLC)828896125 _z(OCoLC)961601655 _z(OCoLC)962705463
037			_a455370 _bMIL
050		4	_aRM301.25 _b.A53 2013
072		7	_aMED _x023000 _2bisacsh
072		7	_aMED _x058170 _2bisacsh
072		7	_aMED _x071000 _2bisacsh
072		7	_aMED _x072000 _2bisacsh
072		7	_aHEA _2eflch
082	0	4	_a615.1/9 _223
049			_aMAIN
245	0	0	_aAnalogue-based drug discovery III / _cedited by János Fischer, C. Robin Ganellin, David P. Rotella.
246	3		_aAnalogue-based drug discovery 3
246	3		_aAnalog-based drug discovery III
264		1	_aWeinheim : _bWiley-VCH, _c[2013]
264		4	_c©2013
300			_a1 online resource (xviii, 385 pages) : _billustrations, portraits
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
588	0		_aOnline resource; title page from PDF title page (viewed June 30, 2014).
505	0	0	_tGeneral Aspects. Pioneer and Analogue Drugs / _rJanos Fischer, C Robin Ganellin, David P Rotella -- _tCompetition in the Pharmaceutical Drug Development / _rChristian Tyrchan, Fabrizio Giordanetto -- _tMetabolic Stability and Analogue-Based Drug Discovery / _rAmit S Kalgutkar, Antonia F Stepan -- _tUse of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / _rMark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- _tDrug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / _rA Ganesan -- _tThienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / _rJoseph A Jakubowski, Atsuhiro Sugidachi -- _tSelective Estrogen Receptor Modulators / _rAmarjit Luniwal, Rachael Jetson, Paul Erhardt -- _tDiscovery of Nonpeptide Vasopressin V2 Receptor Antagonists / _rKazumi Kondo, Hidenori Ogawa -- _tThe Development of Cysteinyl Leukotriene Receptor Antagonists / _rPeter R Bernstein -- _tCase Studies. The Discovery of Dabigatran Etexilate / _rNorbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- _tThe Discovery of Citalopram and Its Refinement to Escitalopram / _rKlaus P Bogeso, Connie Sanchez -- _tTapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / _rHelmut Buschmann -- _tNovel Taxanes: Cabazitaxel Case Study / _rHerve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- _tDiscovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / _rSrikanth Venkatraman, Andrew Prongay, George F Njoroge -- _tA New-Generation Uric Acid Production Inhibitor: Febuxostat / _rKen Okamoto, Shiro Kondo, Takeshi Nishino.
504			_aIncludes bibliographical references and index.
520			_a"Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and--together with the previous volumes--constitutes the first systematic approach to drug analogue development"--Publisher's website.
650		0	_aDrug development.
650		7	_aMEDICAL _xDrug Guides. _2bisacsh
650		7	_aMEDICAL _xNursing _xPharmacology. _2bisacsh
650		7	_aMEDICAL _xPharmacology. _2bisacsh
650		7	_aMEDICAL _xPharmacy. _2bisacsh
650		7	_aDrug development. _2fast _0(OCoLC)fst00898670
655		4	_aElectronic books.
655		7	_aElectronic books. _2local
700	1		_aFischer, János, _eeditor.
700	1		_aGanellin, C. R. _q(C. Robin), _eeditor.
700	1		_aRotella, David P., _eeditor.
776	0	8	_iPrint version: _tAnalogue-based drug discovery III. _dWeinheim : Wiley-VCH, [2013] _z9783527330737 _w(OCoLC)825555931
856	4	0	_uhttp://onlinelibrary.wiley.com/book/10.1002/9783527651085 _zWiley Online Library [Free Download only for SUST IP]
938			_aCoutts Information Services _bCOUT _n24876696 _c130.00 GBP
938			_aEBL - Ebook Library _bEBLB _nEBL1123660
938			_aebrary _bEBRY _nebr10662582
938			_aEBSCOhost _bEBSC _n542882
938			_aIngram Digital eBook Collection _bIDEB _ncis24876696
938			_aYBP Library Services _bYANK _n9985301
938			_aYBP Library Services _bYANK _n10226219
938			_aYBP Library Services _bYANK _n10247713
994			_a92 _bDG1
999			_c63890 _d63890